Latest news with #Directors
Toronto Star
4 days ago
- Business
- Toronto Star
Andrew Peller Limited Announces Second Quarter Fiscal 2026 Dividend
GRIMSBY, Ontario, Aug. 06, 2025 (GLOBE NEWSWIRE) — The Board of Directors of Andrew Peller Limited (ADW.A / ADW.B) (the 'Company') announced today that it has approved a quarterly common share dividend of $0.0615 per Class A Share and $0.0535 per Class B Share to be paid on October 10, 2025, to shareholders of record on September 30, 2025. The Company has consistently paid common share dividends since 1979. The Company currently designates all dividends paid as 'eligible dividends' for purposes of the Income Tax Act (Canada) unless indicated otherwise.
Economic Times
5 days ago
- Business
- Economic Times
Pidilite Industries board to meet today to consider first bonus issue in 15 years
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The Board of Directors of Fevicol-maker Pidilite Industries is set to meet today, Wednesday, August 6, to consider key corporate matters, including a proposal to issue bonus shares — the company's first such move in 15 a prior exchange filing, the company had informed that the board meeting would, inter alia, take up approval of the unaudited financial results for the quarter ended June 30, 2025. Alongside the quarterly earnings, the board will also discuss the declaration of a special interim dividend for the financial year 2025–26.'In compliance with Regulation 29 of the SEBI Listing Regulations, we wish to inform you that at the said meeting, the Board would also consider the following proposal(s): i. Declaration of a Special Interim Dividend on the equity shares of the Company, for the Financial Year 2025-26; and ii. Issue of bonus shares in accordance with the applicable provisions and subject to approval of Shareholders of the Company,' the company had proposal for issuing bonus shares, if approved by the board, would be subject to shareholder approval as approved, this will be the first bonus share issue by the company after its last 1:1 bonus share issue in March 2010, according to Trendlyne company also confirmed that the trading window for dealing in securities remains closed until August 8, in line with SEBI details regarding the bonus ratio, record date, or quantum of dividend, if any, are expected to be disclosed after the outcome of today's meeting.A bonus share issue is when a company distributes additional shares to its existing shareholders free of cost, in proportion to their current holdings. For example, in a 1:1 bonus issue, shareholders receive one extra share for every share they already is relevant because it rewards shareholders without affecting the company's cash reserves and often signals management's confidence in the company's future the overall value of a shareholder's investment remains the same immediately after the issue (since the share price adjusts accordingly), the number of shares held increases, potentially improving liquidity and making the stock more affordable for new 11:15 am, shares of Pidilite Industries were trading flat at Rs 2,998.40 on the read: Reliance Power shares down 31% in 1 month. Should you buy the dip or steer clear? (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Mint
5 days ago
- Business
- Mint
Brewery stock rebounds as board sets meeting to declare dividend record date, Q1 results 2025
BCL Industries share price saw a recovery during Tuesday's trading session and closed above the day's low after the company announced that its Board of Directors meeting will take place on August 12, 2025. According to the filing, the board will review and approve the unaudited financial results, both standalone and consolidated, for the quarter ending June 30, 2025. The agenda will also include discussions about relocating the company's registered office within the municipal limits of Bathinda city. Additionally, the Board will discuss setting the date and time for the 49th Annual General Meeting of the company, along with other relevant issues. The meeting will also establish the record date for declaring dividends for the financial year 2024–25. Importantly, during the presentation of its Q4 results in May, BCL Industries' board announced a dividend of 26 percent on each Re 1 share for the relevant period. This 26 percent dividend equates to a payout of Re 0.26. "Recommended an equity dividend of 26 paisa per share on face value of Re 1 each, i.e. for the financial year ended March 31, 2025, which shall be subject to declaration by the Members at the 49th AGM of the Company," said BCL Industries in a filing then. BCL Industries share price today closed at ₹ 44.30 apiece on the BSE, the stock touched an intraday high at ₹ 44.89 per share, and an intraday low of ₹ 43.95 apiece. According to Anshul Jain, Head of Research at Lakshmishree Investments, BLC Industries share price is currently trading in a broad range of 50–35, with some early signs of institutional accumulation. However, the overall price action lacks strong bullish confirmation, indicating that the base is still under development. 'The stock appears to need more time to consolidate and build a stronger foundation before any sustainable upmove. A decisive breakout above 50, supported by rising volumes, will be the key trigger to confirm strength. Once that level is breached, the stock has the potential to move toward the 60 mark in the short to medium term,' said Jain. Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.
Time of India
6 days ago
- Business
- Time of India
IndusInd Bank shares in focus as board approves Rajiv Anand's appointment as MD, CEO
Shares of IndusInd Bank are expected to be in focus on Tuesday after the bank's Board of Directors approved the appointment of Rajiv Anand as the Managing Director and Chief Executive Officer. The appointment will be effective from August 25 for a term of three years, according to a statement issued by the bank. Rajiv Anand brings with him over 35 years of experience in the banking and financial services industry. In his most recent role, he served as Deputy Managing Director at Axis Bank , where he played a key role in scaling both retail and corporate businesses. His professional background spans multiple domains, including capital markets, treasury, and asset management. The bank described Anand's track record as 'exemplary,' citing his deep expertise and leadership in various banking functions. The Board noted that the appointment reflects IndusInd Bank's commitment to 'expeditiously identifying the MD & CEO with the right competencies and strong values.' 'On behalf of the Board, I congratulate Rajiv Anand on his appointment as the MD & CEO of the Bank. The Board looks forward to working closely with Rajiv and the management team to deliver strong and robust growth while prioritising the highest standards of governance,' said Sunil Mehta, the Chairman of the Board of Directors of IndusInd Bank. 'The Board would like to express its gratitude to the Reserve Bank of India for its invaluable support throughout the process. The Board, the Management team, and all employees look forward to welcoming Rajiv to the IndusInd family and growing this franchise to its full potential," he added. Shares of IndusInd Bank closed 2.6% higher at Rs 803.90 on the BSE on Monday. Also read: Tata Investment announces first-ever stock split in 1:10 ratio; check details on record date ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Business Wire
01-08-2025
- Business
- Business Wire
Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, announces significant changes within the Board of Directors. As mentioned in the press release dated July 29, 2025 following the agreement signed by Poxel and its directors with the senior creditor of the Company, and in the context of the filing for the insolvency (' déclaration de cessation des paiements ') and request for opening of reorganization proceedings (' redressement judiciaire ') with the Court for Economic Activities of Lyon, all the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn and Mr. Khoso Baluch, have submitted their resignations with immediate effect as of July 31, 2025. At its meeting on July 31, 2025, the Board of Directors of the Company decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe; Mr. Nicolas Trouche; Mr. Amit Kohli; Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Regarding the independence criteria adopted by the Board of Directors and derived from the MiddleNext Code, Ms. Sophie Jacq Lapointe and Mr. Amit Kohli are considered to be independent directors. As Mr. Alexandre Bragadir is an employee of IPF Partners, which is one of the Company's partners and creditors (but not a shareholder), he cannot be considered independent. Due to his appointment as Chief Executive Officer, Mr. Nicolas Trouche cannot be considered independent either. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors, as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Mr. Thomas Kuhn also informed the Board of Directors of his resignation from his position as Chief Executive Officer, with immediate effect as of July 31, 2025. The Board of Directors then unanimously appointed Mr. Nicolas Trouche as Chief Executive Officer of the Company. Sophie Jacq Lapointe With over 20 years of experience in the pharmaceutical industry, Sophie has held numerous executive roles and has contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Nicolas Trouche Nicolas started with D&I in 2021, a firm specialized in restructuring companies in special situations. Nicolas started in R&D and development of hardware components for robotics. He joined Valeo group where he developed a complete career in technical, project and division management positions in France, Germany and Spain. Moving to Faurecia, he managed the reorganization of one important plant within Seating Business Group. He started at Kuka in 2008 as CEO of Kuka Systems France to conduct the full restructuring of this company during subprime crisis, then managed participations of French and foreign investment funds in operational restructuring contexts, construction of green fields in Slovakia, Mexico and China, equity and build-up negotiations. In particular as CEO of a Tier 2 equipment group that he led from €70M to €150M in turnover. Senior advisor for a German fund, he also bought, managed and then sold companies in the BtoB service: industrial equipment, engineering services, electrical, PLC and Robotics. As a D&I partner, he has worked in several technology start-ups and has developed and restructured B2B industrial and commercial and service companies. Nicolas is an engineer in electrical engineering with a PhD in robotics. Amit Kohli Amit Kohli has over 3 decades of leadership experience operating at intersection of science, finance and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company's $75M sale to Medicus (NASDAQ: MDCX). Mr Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson and Sanofi, encompassing sales, marketing, finance, supply chain and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe. About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is otherwise not responsible for the content of external hyperlinks referred to in this press release.
